CG From the
-
Universalizing Allogeneic Cell Therapies With Cord-Blood-Derived Stem Cells
9/26/2023
Coeptis Therapeutics' new CSO, Dr. Colleen Delaney, explains why she thinks umbilical cord blood is the best source of starting material for allogeneic cell therapies.
-
CBER’s Dr. Peter Marks, ARM’s Mike Lehmicke On Genome Editing Technologies
9/19/2023
Recent conversations with some of the industry's top experts show genome editing technologies are here to stay and evolving rapidly.
-
Excision BioTherapeutics’ CSO Discusses Dual-Guide RNA’s Impact On Gene Editing
9/15/2023
Excision BioTherapeutics' CSO, Dr. TJ Cradick, explains Excision's dual-guide RNA approach to cure chronic, viral infectious diseases.
-
Challenges Stunting The AAV Field
9/7/2023
DeciBio conducted a survey among leaders in the AAV vector space to identify key pain points in the field. Dr. Carl Schoellhammer discusses these results and what they mean for the industry moving forward.
-
Regulating the CGT Workflow To Improve Patient Safety
8/31/2023
In case you missed it, our most recent Cell & Gene Live, Regulating the CGT Workflow To Improve Patient Safety, featuring expert panelists Nimi Chhina, Ph.D., J.D. Executive Director, Head of Global R&D and Regulatory Policy Global Regulatory Affairs, Worldwide Research & Development at BioMarin Pharmaceutical, and Bob Pietrusko, Pharm.D., Chief Regulatory & Quality Officer at Vor Biopharma, is available on demand in its entirety.
-
Bayer, BlueRock’s Parkinson’s Trial On Course For Phase 2
8/29/2023
Bayer, BlueRock's stem cell therapy for Parkinson's Disease preps for Phase 2.
-
Akamis Bio Takes On Advanced Solid Tumors
8/23/2023
Akamis Bio’s CEO, Dr. Howard Davis, explains the company's T-SIGn platform, the NG-350A trial, and how T-SIGn may impact CAR-T for solid tumors.
-
Understanding Donor Characteristics to Improve Allogeneic Cell Therapy Outcomes
8/7/2023
Efficiencies in donor selection reduce uncertainties about human leukocyte antigen (HLA) and improve patient outcomes.
-
Automation’s Role In Cell Therapy Manufacturing
7/31/2023
The need for standardization and automation are critical drivers of innovation in cell therapy manufacturing. Implementation of an automated workflow minimizes open processes and manual touchpoints, increases reproducibility, and improves traceability. This has the potential to reduce manufacturing failures and lower the cost of goods sold, thereby facilitating increased patient access.
-
Excision BioTherapeutics & Guide RNA
7/27/2023
Excision’s CEO Daniel Dornbusch to dig into its CRISPR-based therapy, EBT-101, as well as Guide RNA (gRNA) and why it is critical to EBT-101’s success.